- FDA reviewing increase in adult prescription stimulant use and ongoing shortages.
- Surge in stimulant dispensing, possibly due to COVID-19 pandemic and relaxed telemedicine regulations.
- Ongoing shortages creating barriers for patients with ADHD.
- FDA collaborating with DEA and other agencies to assess appropriate use and mitigate disruptions.
- Data do not suggest a proportional rise in nonmedical stimulant use.
- Despite increased prescribing, shortages persist, with collaborative efforts ongoing to alleviate these shortages.
- Stimulant product labeling includes a boxed warning about risks of misuse and addiction, updated in 2023.
Source: JAMA Psychiatry
